REG - Target H'care REIT - Publication of Supplementary Prospectus

Target Healthcare ReitAnnouncement

18/09/2019 14:05

RNS Number : 8400M
Target Healthcare REIT PLC
18 September 2019
 


TARGET HEALTHCARE REIT PLC        
18 September 2019
LEI: 213800RXPY9WULUSBC04
 
PUBLICATION OF SUPPLEMENTARY PROSPECTUS
Target Healthcare REIT plc (the "Company") has today published a supplementary prospectus approved by the Financial Conduct Authority. The publication of the supplementary prospectus is a regulatory requirement under the Prospectus Regulation Rules following the publication of the Group's Annual Report and Financial Statements for the year ended 30 June 2019.
The supplementary prospectus is supplemental to, and should be read in conjunction with, the prospectus published by the Company on 21 June 2019.
A copy of the supplementary prospectus will shortly be available for inspection at the National Storage Mechanism which is located at http://www.morningstar.co.uk/uk/NSM
The supplementary prospectus is also available in electronic form on the Company's website at www.targethealthcarereit.co.uk and available for collection during normal business hours on any day (Saturday, Sunday and public holidays excepted) until 20 June 2020 at the offices of Dickson Minto W.S., Broadgate Tower, 20 Primrose Street, London EC2A 2EW.
The Company's legal entity identifier: 213800RXPY9WULUSBC04
 



Target Fund Managers Limited












Kenneth MacKenzie






01786 845 912




Gordon Bland






01786 845 920


















Stifel Nicolaus Europe Limited












Mark Young


mark.young@stifel.com


+44 20 7710 7600




Neil Winward


neil.winward@stifel.com


+44 20 7710 7600




Tom Yeadon


tom.yeadon@stifel.com


+44 20 7710 7600


















FTI Consulting












Dido Laurimore


TargetHealthcare@fticonsulting.com


+44 20 3727 1000




Claire Turvey












Richard Gotla











 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PSPKMGMLZRRGLZM